BioMedNewsBreaks

MondayJul 22, 2024 12:06 pm

BioMedNewsBreaks — Onassis Holdings Corp. (ONSS) Enters Agreement with Dalmore Group for Reg A+ Offering

Onassis Holdings (OTC: ONSS), a wellness- and biotech-focused holding company, has launched a round of Regulation A+ financing. The company has entered an agreement with Dalmore Group for the fundraising initiative. According to the announcement, Reg A+ funding offers a streamlined method for companies to raise up to $75 million a year from the public. “In aligning with Dalmore Group, Onassis looks to leverage the investment bank's prowess in capital raising through Regulations A+, CF and D,” stated the announcement. “Since 2021, Dalmore has on-boarded over 270 Reg A+ issuers, establishing itself as a leader in Reg A+ financing services. With over…

Continue Reading

FridayJul 19, 2024 10:27 am

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Execs to Participate in July 25 Investor Webinar

Nutriband (NASDAQ: NTRB), a pharmaceutical company with a special focus on transdermal technologies, is inviting investors to a live webinar. Scheduled for July 25, 2024, at 4:15 p.m. ET, this exclusive event will be hosted by RedChip Companies. During the webinar, Nutriband Chairman and President Serguei Melnik and CEO Gareth Sheridan will share insights into the company’s current operations and upcoming milestones. To register for the free webinar, visit https://ibn.fm/ZZkgn To view the full press release, visit https://ibn.fm/xnDGN About Nutriband Inc. Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Its lead product under development…

Continue Reading

WednesdayJul 17, 2024 1:06 pm

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at the 73rd Emerging Growth Conference

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc. is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). The company is presenting at the 73rd Emerging Growth Conference, scheduled for July 17-18, 2024. Clene’s presentation is slated to begin at 4:45 p.m. EDT on July 18, with Rob Etherington, Clene’s President and CEO, and Morgan Brown, Clene’s CFO, giving the presentation. To view the full press release, visit https://ibn.fm/kt4FO About Clene Inc. Clene (along with…

Continue Reading

WednesdayJul 17, 2024 10:25 am

BioMedNewsBreaks – HealthLynked Corp. (HLYK) Enters Strategic Partnership to Support Rollout of Telemedicine Services across the US

HealthLynked (OTCQB: HLYK), a trailblazer in healthcare technology, is announcing a strategic partnership with HC Smart, Inc., a national telemedicine provider. The partnership, set to go live within the next four weeks, is expected to extend HealthLynked’s telemedicine services across the U.S. as well as significantly enhance the company’s offerings and accessibility. The announcement stated that the collaboration will integrate HC Smart’s advanced telemedicine capabilities into HealthLynked’s existing platform, providing nationwide coverage to all HealthLynked members. This initiative will offer HealthLynked Network members access to high-quality healthcare from the comfort of their homes by enabling reduced-cost telemedicine consultations as part…

Continue Reading

TuesdayJul 16, 2024 3:38 pm

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Names New Medical Advisory Board Member

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, has appointed a new member to its medical advisory board. According to the announcement, Mark Gilbert, MD, will be joining the board, bringing board membership to eight. A scientist emeritus at the National Institutes of Health (“NIH”), Gilbert served as chief of the neurooncology branch at NIH for a decade. During that time, Gilbert facilitated a team of laboratory and clinical investigators involved in groundbreaking research that advanced science in the brain tumor field. In addition to his experience at NIH, Gilbert practiced under world-renowned…

Continue Reading

TuesdayJul 16, 2024 3:00 pm

BioMedNewsBreaks — Bluejay Diagnostics Inc. (NASDAQ: BJDX) Closes $8.75M Underwritten Public Offering

Bluejay (NASDAQ: BJDX), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, recently announced the closing of a firm commitment underwritten public offering. Expected gross proceeds to the company were approximately $8.75 million. The base offering consisted of 5,368,098 common units or prefunded units, each unit consisting of one share of the company’s common stock or one pre-funded warrant to purchase one share of common Stock, two Class C warrants each to purchase one share of common stock and one Class D warrant to purchase such number of shares of…

Continue Reading

TuesdayJul 16, 2024 2:41 pm

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Exec to Present at Upcoming Virtual Investor Closing Bell Series

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured in tomorrow’s Virtual Investor Closing Bell Series. According to the announcement, CNS Pharmaceuticals CEO John Climaco will be presenting via a live video webcast at 4 p.m. on July 17. The presentation will include a corporate overview and will also feature a live question-and-answer period. A replay of the webcast will be available following the live presentation and will be accessible for 90 days. To view the presentation, visit https://ibn.fm/Uy7c6 To…

Continue Reading

TuesdayJul 16, 2024 1:05 pm

BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Secures FDA Approval for New Form of Buntanetap

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced receipt of approval from the U.S. Food and Drug Administration (“FDA”) to transition to a new solid form of buntanetap in future clinical trials. “In June 2024, Annovis announced the filing of a composition of matter patent for the new crystal form of buntanetap and a provisional patent for the manufacturing process of this new form,” the announcement reads. “The company conducted comprehensive bridge studies in various solvents and in animals, comparing the old…

Continue Reading

MondayJul 15, 2024 11:15 am

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Obtains Notice of Allowance for Key Trademark Identified as ‘Integral’ to Platform Technology

Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceutical products, has received a Notice of Allowance from the United States Patent and Trademark Office (“USPTO”). According to the announcement, the notice means that the USPTO anticipates granting the trademark registration covering the mark “AVERSA” after completing administrative processes. Nutriband's proprietary AVERSA(TM) abuse deterrent transdermal technology works to incorporate aversive agents into transdermal patches that make an experience unpleasant, thereby discouraging abuse of substances. This technology is especially significant for drugs such as fentanyl, which have a high potential for abuse. The company’s lead product under development is AVERSA Fentanyl. Nutriband is…

Continue Reading

MondayJul 15, 2024 10:40 am

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases Successful Preclinical Results In-Vivo Proof-of-Concept Psoriatic Human Skin Model Study

Scinai Immunotherapeutics (NASDAQ: SCNI), a biotechnology company focused on developing inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, is reporting recent study results. According to the announcement, the successful in-vivo preclinical results are from SCNI’s innovative anti IL-17A/F VHH antibody fragment (“NanoAb”), which is being studied as a local, first-of-its-kind, intralesional biological treatment for from mild to moderate plaque psoriasis. An estimated million patients are diagnosed with plaque psoriasis in the United States, Japan and Europe. Scinai's product candidate is designed to address the major shortcomings of…

Continue Reading